Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to be announcing its earnings results before the market opens on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.21. The business had revenue of $19.89 million for the quarter, compared to the consensus estimate of $5.97 million. On average, analysts expect Karyopharm Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of KPTI stock traded down $0.36 during mid-day trading on Friday, reaching $10.86. 13,611 shares of the company’s stock traded hands, compared to its average volume of 1,225,496. Karyopharm Therapeutics has a 12 month low of $9.00 and a 12 month high of $21.71. The company has a market cap of $638.94 million, a price-to-earnings ratio of -3.83 and a beta of 3.75.
A number of equities research analysts have recently issued reports on KPTI shares. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 29th. ValuEngine downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research report on Wednesday, July 25th. Robert W. Baird reissued a “buy” rating and set a $25.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Finally, BidaskClub downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Karyopharm Therapeutics presently has an average rating of “Buy” and an average target price of $22.90.
In related news, insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction on Thursday, October 18th. The shares were sold at an average price of $12.63, for a total value of $126,300.00. Following the completion of the transaction, the insider now owns 713,510 shares of the company’s stock, valued at approximately $9,011,631.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Kauffman sold 12,500 shares of the company’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $18.04, for a total transaction of $225,500.00. Following the completion of the transaction, the chief executive officer now directly owns 512,143 shares of the company’s stock, valued at approximately $9,239,059.72. The disclosure for this sale can be found here. Insiders sold a total of 827,266 shares of company stock valued at $16,495,001 in the last ninety days. 13.26% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Karyopharm Therapeutics stock. Bank of New York Mellon Corp boosted its stake in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 28.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 214,018 shares of the company’s stock after purchasing an additional 46,911 shares during the quarter. Bank of New York Mellon Corp owned about 0.35% of Karyopharm Therapeutics worth $3,636,000 as of its most recent SEC filing. 71.84% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
See Also: Average Daily Trade Volume Explained
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.